The US Food and Drug Administration has begun an initiative to rewrite the labels on drugs prescribed for attention deficit hyperactivity disorder (ADHD) to reflect the agency's concern about possible side effects, including hallucinations and suicidal tendencies.
Comments (0)
Please sign in to leave a comment.
No comments yet. Be the first to comment!